Among patients with intrahepatic tumor progression, the median PFS1 was 5.3 months in the TACE+LEN group and 10.0 months in the TACE+LEN+PD-1 group, with no statistically significant difference between the two groups (HR=1.759, 95% CI 0.949-3.259, P=0.072) (Figure 3). This evidence concerns the gene PDCD1 and neoplasm.